# Ken Herrmann

Source: https://onco.cc/people/ken-herrmann/  
OnCo record `ken-herrmann` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.

## Summary

Ken Herrmann was a lead investigator of VISION and of the German multicentre 177Lu-PSMA-617 registry, and leads the Essen theranostics centre that has treated thousands of patients with PSMA and somatostatin receptor radioligands. He has chaired the EANM oncology committee, co-authored the Lancet Oncology series on theranostics, and leads trials of alpha emitters and new targets such as FAP.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: radioligand; nuclear-medicine; germany
- Role: Chair of Nuclear Medicine, University Hospital Essen
- Specialisms: Theranostics; PSMA radioligand therapy; Nuclear medicine; Radiopharmaceutical trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [FAPI PET](https://onco.cc/technologies/fapi-pet/), [PSMA PET](https://onco.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [FAP](https://onco.cc/targets/fap/), [PSMA](https://onco.cc/targets/psma/)
- drugs: [Lutetium-177 dotatate](https://onco.cc/drugs/lutathera/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/)
- institutions: [European Association of Nuclear Medicine](https://onco.cc/institutions/eanm/), [West German Cancer Center (WTZ), University Hospital Essen](https://onco.cc/institutions/essen-wtz/)
- trials: [VISION](https://onco.cc/trials/vision/)
- key papers: [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://onco.cc/key-papers/paper-vision-nejm-2021/)

---
JSON: https://onco.cc/api/v1/entities/ken-herrmann.json